

University Hospitals Sussex NHS Foundation Trust - Eastern Sites
Clinical Trials Delivery Performance
Q2 2021 2022

Royal Sussex County Hospital
Royal Alexandra Children's Hospital
Princess Royal Hospital
Brighton General Hospital
Sussex Eye Hospital

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/WM/0207	222284	Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation	Range Agreed	10	20	Date Agreed	30/06/2019	10	15/10/2020	10	Withdrawn By Sponsor
19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis	Number Agreed	2	2	Date Agreed	30/06/2020	0	29/10/2020	0	Withdrawn By Host
18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Range Agreed	1	4	Not Available / Not Agreed			16/11/2020	0	Recruitment Finished
20/YH/0317	288552	Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COVS.2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Number Agreed	330	330	Not Available / Not Agreed			30/01/2021	348	Recruitment Finished
20/EE/0135	282213	Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)	Number Agreed	6	6	Not Available / Not Agreed			21/06/2021	12	Recruitment Finished
17/YH/0311	229294	A Modular, Multipart, Multiarm, Open-label, Phase IIIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies	Range Agreed	4	6	Date Agreed	31/12/2020	0	21/07/2021	0	Recruitment Finished